Market Overview

UPDATE: Morgan Stanley Initiates Quintiles Transnational at Overweight on CRO Market Leader Position

Benzinga's M&A Chatter for Tuesday May 3, 2016
The Market In 5 Minutes: Do Or Die
PRA Health Sciences: Leading CRO Firm With Compelling Growth Story (Seeking Alpha)

In a report published Tuesday, Morgan Stanley analyst Ricky R. Goldwasser initiated coverage on Quintiles Transnational (NYSE: Q) with an Overweight rating and $51.00 price target.

In the report, Morgan Stanley noted, “As the contract research organization (CRO) market leader with 11% share of clinical outsourcing, a diversified customer base and backlog visibility, we believe Quintiles is best positioned to benefit from the growth in biopharmaceutical R&D outsourcing.”

Quintiles Transnational closed on Monday at $43.53.

Latest Ratings for Q

May 2016Wells FargoDowngradesOutperformMarket Perform
May 2016CitigroupDowngradesBuyNeutral
May 2016BairdDowngradesOutperformNeutral

View More Analyst Ratings for Q
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Initiation Analyst Ratings


Related Articles (Q)

View Comments and Join the Discussion!